Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy

Abstract Background Therapeutic strategies for unresectable hepatocellular carcinoma (u‐HCC) in geriatric patients are important for real‐world practice. However, there remain no established biomarkers or therapeutic strategies regarding the best second‐line agent after atezolizumab plus bevacizumab...

Full description

Bibliographic Details
Main Authors:	Shuhei Sekiguchi, Kaoru Tsuchiya, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Leona Osawa, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi
Format:	Article
Language:	English
Published:	Wiley 2022-11-01
Series:	Cancer Reports
Subjects:	1 Geriatric 8 score hepatocellular carcinoma 2 lenvatinib 4 sorafenib 3
Online Access:	https://doi.org/10.1002/cnr2.1613

Similar Items

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01)

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2021-08-01)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
by: Soo Young Kim, et al.
Published: (2018-10-01)

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
by: Young Eun Chon, et al.
Published: (2024-07-01)

Hand–foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer
by: Elisa Minaldi, et al.
Published: (2024-08-01)

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study
by: Xiumei Jiang, et al.
Published: (2025-03-01)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
by: Chen B, et al.
Published: (2022-12-01)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
by: Jia Luo, et al.
Published: (2022-12-01)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
by: Yongkang Xu, et al.
Published: (2022-09-01)

Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with Extrahepatic Metastasis
by: Duan WB, et al.
Published: (2024-05-01)

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
by: Kenta Takaura, et al.
Published: (2022-01-01)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023-10-01)

Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018–2021) compared to the sorafenib era (2008–2018)
by: Chloe A. Lim, et al.
Published: (2024-07-01)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
by: I-Cheng Lee, et al.
Published: (2022-10-01)

Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid
by: Jan Stępniak, et al.
Published: (2022-11-01)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-02-01)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-06-01)

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma
by: Moxuan Wang, et al.
Published: (2024-10-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
by: Hongyu Gong, et al.
Published: (2023-03-01)

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
by: Paula Jimenez‐Fonseca
Published: (2022-10-01)

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
by: S. Morelli, et al.
Published: (2017-07-01)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
by: Shun Kaneko, et al.
Published: (2022-01-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations
by: Philipp Berning, et al.
Published: (2024-02-01)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
by: Maria Cerreto, et al.
Published: (2023-09-01)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020-06-01)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023-06-01)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
by: Clarissa Lam, et al.
Published: (2023-10-01)

Nanomaterials for liver cancer targeting: research progress and future prospects
by: Jiahong Xu, et al.
Published: (2025-02-01)

Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells
by: Zengbin Wang, et al.
Published: (2024-05-01)

Galactosylated Polymer/Gold Nanorods Nanocomposites for Sustained and Pulsed Chemo-Photothermal Treatments of Hepatocarcinoma
by: Gaetano Giammona, et al.
Published: (2022-11-01)

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
by: Frontiers Production Office
Published: (2023-04-01)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
by: Lei Jiang, et al.
Published: (2023-02-01)

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
by: Domenico Ciliberto, et al.
Published: (2023-08-01)

Thrombotic microangiopathy associated with lenvatinib therapy
by: Macarena Contreras Angulo, et al.
Published: (2023-04-01)

Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension
by: Koji Yamashita, et al.
Published: (2022-11-01)